Summary
Bromocriptine was used as a treatment for Parkinson's disease in 15 patients for 20 weeks. Immunoreactive plasma lutrophin (LH), follitrophin (FSH), prolactin, and somatotrophin (GH, growth hormone) concentrations were analysed before and during the treatment.
Plasma prolactin levels were very markedly reduced during treatment.
Plasma lutrophin levels were increased statistically significantly in female patients, but not in male patients. No changes were noticed in follitrophin levels, but plasma somatotrophin levels were reduced during treatment.
No correlations were found between the degree of clinical response and changes in plasma gonadotrophin and somatotrophin. This suggests that the effects of bromocriptine on extrapyramidal and neuroendocrine dopaminergic neurons are unrelated.
We suggest careful and frequent controls of neuroendocrine secretion patterns in patients with Parkinson's disease who are treated with high doses of dopamine receptor stimulators, since the responses of some pituitary hormones to bromocriptine are very marked.
This is a preview of subscription content, log in via an institution to check access.
References
Besser, G. M., Parke, L., Edwards, C. R. W., Forsyth, I. A., McNeilly, A. S. Galactorrhea: successful treatment with reduction of plasma prolactin levels by brom-ergocryptine. Brit. med. J.3, 669–672 (1972).
Calne, D. B., Teychenne, P. F., Claveria, L. E., Eastman, R., Greenacre, J. K., Petrie, A. Bromocriptine in Parkinsonism, Brit. med. J.4, 442–444 (1974 a).
Calne, D. B., Leigh, P. N., Teychenne, P. F., Bamji, A. N., Greenacre, J. K. Treatment of Parkinsonism with Bromocriptine. LancetII, 1355–1356 (1974 b).
Camanni, F., Massara, F., Fassio, V., Molinatti, G. M., Müller, E. E. Effect of five dopaminergic drugs on plasma growth hormone levels in acromegalic subjects. Neuroendocrinology19, 227–240 (1975).
Corrodi, H., Fuxe, K., Hökfelt, T., Lidbrink, P., Ungerstedt, U. Effect of ergot drugs on central catecholamine neurons: Evidence for a stimulation of central dopamine neurons. J. Pharm. Pharmacol.25, 409–412 (1973).
Del Pozo, E., Brun del Re, R., Varga, L., Friesen, H. G. The inhibition of prolactin secretion in man by CB 154 (2-Br-alfa-ergocryptine). J. clin. Endocr.35, 768–771 (1972).
Del Pozo, E., Friesen, H., Burmeister, P. Endocrine profile of a specific prolactin inhibitor: Br-ergocryptine (CB 154). Schweiz. med. Wschr.103, 847–848 (1973).
Den Hollander, F. G., Scbuurs, A. H., van Hell, H. Radioimmunoassays for human gonadotrophins and insulin employing a “double-antibody solid phase” technique. J. Immunological Methods1, 247–262 (1972),
Fuxe, K., Corrodi, H., Hökfelt, T., Lidbrink, P., Ungerstedt, U. Ergocornine and 2-Br-alfa-ergocryptine. Evidence for prolonged dopamine receptor stimulation. Medical Biology52, 121–132 (1974).
Gerlach, J. Effect of CB 154 (2-bromo-alfa-ergocryptine) on paralysis agitans compared with madopar in a double-blind, cross-over trial. Acta Neurol. Scandinav.53, 189–200 (1976).
Mueller, G. P., Simpkins, J., Meites, J., Moore, K. E. Differential effects of dopamine agonists and haloperidol on release of prolactin, thyroid stimulating hormone, growth hormone and luteinizing hormone in rats. Neuroendocrinology20, 121–135 (1976).
Parkes, J. D., Debono, A. G., Marsden, C. D. Bromocriptine in Parkinsonism: long-term treatment, dose response, and comparison with levodopa. J. Neurol. Neurosurg. Psychiat.39, 1101–1108 (1976).
Polleri, A., Carolei, A., Rolandi, E., Masturzo, P., Meco, G., Agnoli, A. Changes in pituitary hormone serum levels in bromocryptine-treated parkinsonian patients. Neuropsychobiology3, 42–48 (1977).
Rinne, U. K., Marttila, R.: Brain dopamine receptor stimulation and the relief of Parkinsonism: Relationship between bromocriptine and levodopa. Europ. Neurol. (in press, 1977).
Sachdev, Y., Tunbridge, W. M. G., Weightman, D. R., Gomez-Pan, A., Duns, A., Hall, R. Bromocriptine therapy in acromegaly. LancetII, 1164–1168 (1975).
Seppälä, M., Ranta, T., Hirvonen, E. Bromocriptine treatment of secondary amenorrhoea. LancetI, 1154–1156 (1976).
Thorner, M. O., McNeilly, A. S., Hagan, C., Besser, G. M. Long-term treatment of galactorrhoea and hypogonadism with bromocriptine. Brit. med. J.II, 419–422 (1974).
Thorner, M. O., Chait, A., Aitken, M., Benker, G., Bloom, S. M., Mortimer, C. H., Sanders, P., Stuart Mason, A., Besser, G. M. Bromocryptine treatment of acromegaly. Brit. med. J.I, 299–303 (1975).
Van der Steeg, H. J., Coelingh Bennink, H. J. T. Bromocriptine for induction of ovulation in normoprolactinaemic post-pill anovulation. LancetI, 502–504 (1977).
Wass, J. A. H., Thorner, M. O., Morris, D. V., Rees Lesley H., Stuart Mason, A., Jones, A. E., Besser, G. M. Long-term treatment of acromegaly with bromocriptine. Brit. med. J.I, 875–878 (1977).
Wide, L. Radioimmunoassays employing immunosorbents. Acta endocr. (Copenh.)63, 207–218 (1969).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hyyppä, M.T., Långvik, V.A. & Rinne, U.K. Plasma pituitary hormones in patients with Parkinson's disease treated with bromocriptine. J. Neural Transmission 42, 151–157 (1978). https://doi.org/10.1007/BF01675354
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF01675354